Inflammatory cytokines and non-small cell lung cancer in a CT-scan screening cohort: Background review of the literature

Cancer Biomarkers

Volumn 16, Issue 2, 2016, Pages 219-233

  Decotiis, Christopher ^a   Hu, Yingjie ^b   Greenberg, Alissa K ^a   Huie, Maryann ^a   Tsay, Jun Chieh J ^a   Pass, Harvey ^b   Goldberg, Judith D ^b   Rom, William N ^a  

^a BELLEVUE HOSPITAL CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

biomarkers; Inflammatory cytokines; non small cell lung cancer

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; BIOLOGICAL MARKER;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER RISK; CANCER SCREENING; CANCER SIZE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYTOKINE RESPONSE; EMPHYSEMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SMOKING; BLOOD; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; COMORBIDITY; LUNG NEOPLASMS; META ANALYSIS; RISK FACTOR; X-RAY COMPUTED TOMOGRAPHY;

BIOMARKERS; CARCINOMA, NON-SMALL-CELL LUNG; COMORBIDITY; CYTOKINES; HUMANS; INFLAMMATION MEDIATORS; LUNG NEOPLASMS; NEOPLASM STAGING; RISK FACTORS; ROC CURVE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84961208384     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-150559     Document Type: Article

References (52)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA: A cancer journal for clinicians 2011, 61(2): 69-90.
2. Nishihara R, Wu K, Lochhead P, Morikawa T, Liao X, Qian ZR, Inamura K, Kim SA, Kuchiba A, Yamauchi M et al: Long-term colorectal-cancer incidence and mortality after lower endoscopy. The New England journal of medicine 2013, 369(12): 1095-1105.
3. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD: Reduced lung-cancer mortality with low-dose computed tomographic screening. The New England journal of medicine 2011, 365(5):395-409.
4. Gill RR, Jaklitsch MT, Jacobson FL: Controversies in lung cancer screening. Journal of the American College of Radiology: JACR 2013, 10(12): 931-936.
5. Greenberg AK, Lu F, Goldberg JD, Eylers E, Tsay JC, Yie TA, Naidich D, McGuinness G, Pass H, Tchou-Wong KM et al: CT scan screening for lung cancer: Risk factors for nodules and malignancy in a high-risk urban cohort. PloS one 2012, 7(7): e39403.
6. Kaminska J, Kowalska M, Kotowicz B, Fuksiewicz M, Glogowski M, Wojcik E, Chechlinska M, Steffen J: Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF-an independent prognostic factor. Oncology 2006, 70(2): 115-125.
7. Li Q, Han Y, Fei G, Guo Z, Ren T, Liu Z: IL-17 promoted metastasis of non-small-cell lung cancer cells. Immunology letters 2012, 148(2): 144-150.
8. Pine SR, Mechanic LE, Enewold L, Chaturvedi AK, Katki HA, Zheng YL, Bowman ED, Engels EA, Caporaso NE, Harris CC: Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. Journal of the National Cancer Institute 2011, 103(14): 1112-1122.
9. Song XY, Zhou SJ, Xiao N, Li YS, Zhen DZ, Su CY, Liu ZD: Research on the relationship between serum levels of inflammatory cytokines and non-small cell lung cancer. Asian Pacific journal of cancer prevention: APJCP 2013, 14(8): 4765-4768.
10. Tas F, Duranyildiz D, Argon A, Oguz H, Camlica H, Yasasever V, Topuz E: Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer. Medical oncology (Northwood, London, England) 2005, 22(4): 353-358.
11. Li Y, Cao ZY, Sun B, Wang GY, Fu Z, Liu YM, Kong QF, Wang JH, Zhang Y, Xu XY et al: Effects of IL-17A on the occurrence of lung adenocarcinoma. Cancer Biology & Therapy 2011, 12(7): 610-616.
12. Arenberg DA, Kunkel SL, Polverini PJ, Morris SB, Burdick MD, Glass MC, Taub DT, Iannettoni MD, Whyte RI, Strieter RM: Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. The Journal of Experimental Medicine 1996, 184(3): 981-992.
13. Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related inflammation. Nature 2008, 454(7203): 436-444.
14. Ekbom A, Helmick C, Zack M, Adami HO: Ulcerative colitis and colorectal cancer. A population-based study. The New England journal of medicine 1990, 323(18): 1228-1233.
15. Chen CJ, Hsu WL, Yang HI, Lee MH, Chen HC, Chien YC, You SL: Epidemiology of virus infection and human cancer. Recent results in cancer research Fortschritte der Krebsforschung Progres dans les recherches sur le cancer 2014, 193: 11-32.
16. Aranda-Hernandez J, Cirocco M, Marcon N: Treatment of Dysplasia in Barrett Esophagus. Clinical Endoscopy 2014, 47(1): 55-64.
17. Augustine MM, Fong Y: Epidemiology and Risk Factors of Biliary Tract and Primary Liver Tumors. Surgical oncology clinics of North America 2014, 23(2): 171-188.
18. Bardan R, Dumache R, Dema A, Cumpanas A, Bucuras V: The role of prostatic inflammation biomarkers in the diagnosis of prostate diseases. Clinical biochemistry 2014.
19. Pereira MI, Medeiros JA: Role of in gastric mucosaassociated lymphoid tissue lymphomas. World journal of gastroenterology: WJG 2014, 20(3): 684-698.
20. Grivennikov SI, Greten FR, Karin M: Immunity, inflammation, and cancer. Cell 2010, 140(6): 883-899.
21. Cho WC, Kwan CK, Yau S, So PP, Poon PC, Au JS: The role of inflammation in the pathogenesis of lung cancer. Expert Opinion on Therapeutic Targets 2011, 15(9): 1127-1137.
22. Kundu JK, Surh YJ: Inflammation: gearing the journey to cancer. Mutation Research 2008, 659(1-2): 15-30.
23. Karin M: Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441(7092): 431-436.
24. Huang M, Wang J, Lee P, Sharma S, Mao JT, Meissner H, Uyemura K, Modlin R, Wollman J, Dubinett SM: Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Research 1995, 55(17): 3847-3853.
25. Lee JM, Yanagawa J, Peebles KA, Sharma S, Mao JT, Dubinett SM: Inflammation in lung carcinogenesis: New targets for lung cancer chemoprevention and treatment. Critical reviews in oncology/hematology 2008, 66(3): 208-217.
26. Dvorak HF: Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. The New England Journal of Medicine 1986, 315(26): 1650-1659.
27. Punturieri A, Szabo E, Croxton TL, Shapiro SD, Dubinett SM: Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research. Journal of the National Cancer Institute 2009, 101(8):554-559.
28. Skillrud DM, Offord KP, Miller RD: Higher risk of lung cancer in chronic obstructive pulmonary disease. A prospective, matched, controlled study. Annals of Internal Medicine 1986, 105(4): 503-507.
29. de Torres JP, Marin JM, Casanova C, Cote C, Carrizo S, Cordoba-Lanus E, Baz-Davila R, Zulueta JJ, Aguirre-Jaime A, Saetta M et al: Lung cancer in patients with chronic obstructive pulmonary disease-incidence and predicting factors. American Journal of Respiratory and Critical Care Medicine 2011, 184(8): 913-919.
30. Walser T, Cui X, Yanagawa J, Lee JM, Heinrich E, Lee G, Sharma S, Dubinett SM: Smoking and lung cancer: The role of inflammation. Proceedings of the American Thoracic Society 2008, 5(8): 811-815.
31. Zaynagetdinov R, Stathopoulos GT, Sherrill TP, Cheng DS, McLoed AG, Ausborn JA, Polosukhin VV, Connelly L, Zhou W, Fingleton B et al: Epithelial nuclear factor-kappaB signaling promotes lung carcinogenesis via recruitment of regulatory T lymphocytes. Oncogene 2012, 31(26): 3164-3176.
32. Zhang Y, Lee TC, Guillemin B, Yu MC, Rom WN: Enhanced IL-1 beta and tumor necrosis factor-alpha release and messenger RNA expression in macrophages from idiopathic pulmonary fibrosis or after asbestos exposure. Journal of Immunology (Baltimore, Md: 1950) 1993, 150(9): 4188-4196.
33. McWilliams A, TammemagiMC,Mayo JR, Roberts H, Liu G, Soghrati K, Yasufuku K, Martel S, Laberge F, Gingras Met al: Probability of cancer in pulmonary nodules detected on first screening CT. The New England Journal of Medicine 2013, 369(10): 910-919.
34. MacMahon H, Austin JH, Gamsu G, Herold CJ, Jett JR, Naidich DP, Patz EF, Jr., Swensen SJ: Guidelines for management of small pulmonary nodules detected on CT scans: A statement from the Fleischner Society. Radiology 2005, 237(2): 395-400.
35. Khan AN, Al-Jahdali HH, Irion KL, Arabi M, Koteyar SS. Solitary pulmonary nodule: A diagnostic algorithm in the light of current imaging technique. Avicenna Journal of Medicine 2011; 1: 39-51. avicennajmed. com?2011/1/2/39/90915.
36. Fisher DT, Appenheimer MM, Evans SS: The two faces of IL-6 in the tumor microenvironment. Seminars in Immunology 2014.
37. Yeh HH, Lai WW, Chen HH, Liu HS, Su WC: Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion. Oncogene 2006, 25(31): 4300-4309.
38. Wang YS, Miao LY, Liu L, Cai HR, Ding JJ, Ren SX, Zhou CC, Schmid-Bindert G: Serum cytokine levels in patients with advanced non-small cell lung cancer: Correlation with clinical outcome of erlotinib treatment. Chinese Medical Journal 2013, 126(20): 3931-3935.
39. Brichory FM, Misek DE, Yim AM, Krause MC, Giordano TJ, Beer DG, Hanash SM: An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proceedings of the National Academy of Sciences of the United States of America 2001, 98(17): 9824-9829.
40. Kuilman T, Michaloglou C, Vredeveld LC, Douma S, van Doorn R, Desmet CJ, Aarden LA, Mooi WJ, Peeper DS: Oncogene-induced senescence relayed by an interleukindependent inflammatory network. Cell 2008, 133(6): 1019-1031.
41. Sunaga N, Kaira K, Tomizawa Y, Shimizu K, Imai H, Takahashi G, Kakegawa S, Ohtaki Y, Nagashima T, Kasahara N et al: Clinicopathological and prognostic significance of interleukin-8 expression and its relationship to KRAS mutation in lung adenocarcinoma. British Journal of Cancer 2014.
42. Orditura M, De Vita F, Catalano G, Infusino S, Lieto E, Martinelli E, Morgillo F, Castellano P, Pignatelli C, Galizia G: Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: relationship with prognosis. Journal of interferon & cytokine research: The official journal of the International Society for Interferon and Cytokine Research 2002, 22(11): 1129-1135.
43. Reppert S, Boross I, Koslowski M, Tureci O, Koch S, Lehr HA, Finotto S: A role for T-bet-mediated tumour immune surveillance in anti-IL-17A treatment of lung cancer. Nature Communications 2011, 2: 600.
44. Smith DR, Kunkel SL, Standiford TJ, Chensue SW, Rolfe MW, Orringer MB, Whyte RI, Burdick MD, Danforth JM, Gilbert AR et al: The production of interleukin-1 receptor antagonist by human bronchogenic carcinoma. The American Journal of Pathology 1993, 143(3): 794-803.
45. Farlow EC, Vercillo MS, Coon JS, Basu S, Kim AW, Faber LP, Warren WH, Bonomi P, Liptay MJ, Borgia JA: A multianalyte serum test for the detection of non-small cell lung cancer. British Journal of Cancer 2010, 103(8): 1221-1228.
46. Daly S, Rinewalt D, Fhied C, Basu S, Mahon B, Liptay MJ, Hong E, Chmielewski G, Yoder MA, Shah PN et al: Development and validation of a plasma biomarker panel for discerning clinical significance of indeterminate pulmonary nodules. Journal of Thoracic Oncology: Official publication of the International Association for the Study of Lung Cancer 2013, 8(1): 31-36.
47. Shiels MS, Pfeiffer RM, Hildesheim A, Engels EA, Kemp TJ, Park JH, Katki HA, Koshiol J, Shelton G, Caporaso NE et al: Circulating inflammation markers and prospective risk for lung cancer. Journal of the National Cancer Institute 2013, 105(24):1871-1880.
48. Engels EA, Wu X, Gu J, Dong Q, Liu J, Spitz MR: Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer. Cancer Research 2007, 67(13): 6520-6527.
49. Chaturvedi AK, Caporaso NE, Katki HA, Wong HL, Chatterjee N, Pine SR, Chanock SJ, Goedert JJ, Engels EA: Creactive protein and risk of lung cancer. Journal of clinical oncology: Official journal of the American Society of Clinical Oncology 2010, 28(16):2719-2726.
50. Bigbee WL, Gopalakrishnan V, Weissfeld JL, Wilson DO, Dacic S, Lokshin AE, Siegfried JM: A multiplexed serum biomarker immunoassay panel discriminates clinical lung cancer patients from high-risk individuals found to be cancerfree by CT screening. Journal of Thoracic Oncology: Official publication of the International Association for the Study of Lung Cancer 2012, 7(4): 698-708.
51. Borgia JA, Basu S, Faber LP, Kim AW, Coon JS, Kaiser-Walters KA, Fhied C, Thomas S, Rouhi O, Warren WH et al: Establishment of a multi-analyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer. Journal of Thoracic Oncology: Official publication of the International Association for the Study of Lung Cancer 2009, 4(3): 338-347.
52. Seike M, Yanaihara N, Bowman ED, Zanetti KA, Budhu A, Kumamoto K, Mechanic LE, Matsumoto S, Yokota J, Shibata T et al: Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. Journal of the National Cancer Institute 2007, 99(16): 1257-1269.